MedTrace Logo

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

NCT00362258 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 797

Last updated 2011-04-04

No results posted yet for this study

Summary

* To evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients.
* To evaluate the benefit of Irbesartan in the reduction of microalbuminuria from baseline (if any at the inclusion visit) in this population.
* To demonstrate the safety of Irbesartan in this population.

Conditions

Interventions

DRUG

Irbesartan (Aprovel)

Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.

Sponsors & Collaborators

Principal Investigators

  • Mosaad I Morsi, MBBCh, MSc · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362258 on ClinicalTrials.gov